Evidence map›Paper›PMID 40672366›Full record

ArticleFrontiers in pharmacology2025

Advanced therapeutic strategy for managing surgical site infections with natural nanoemulsion-antimicrobial combination.

Fatma Alshehri, Nada K Alharbi, AbdelNaser Zaid, Amira H Eltrawy, Shereen Fawzy, Attia M Gabr, Sawsan A Zaitone, Majid Alhomrani, Abdulhakeem S Alamri, Rasha A Mosbah and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fatma AlshehriDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Nada K AlharbiDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
AbdelNaser ZaidDepartment of Surgery, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Amira H EltrawyDepartment of Anatomy, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
Shereen FawzyDepartment of Medical Microbiology, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
Attia M GabrDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, Saudi Arabia.
Sawsan A ZaitoneDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
Majid AlhomraniDepartment of Clinical Laboratories Sciences, The Faculty of Applied Medical Science, Taif University, Taif, Saudi Arabia.
Abdulhakeem S AlamriDepartment of Clinical Laboratories Sciences, The Faculty of Applied Medical Science, Taif University, Taif, Saudi Arabia.
Rasha A MosbahInfection Control Unit, Zagazig University Hospital, Zagazig, Egypt.
Rana ElshimyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Alhram Canadian University, Giza, Egypt.
Abdallah Tageldein MansourFish and Animal Production Department, College of Agriculture and Food Sciences, King Faisal University, Al-Ahsa, Saudi Arabia.
Mahmoud M BendaryDepartment of Microbiology and Immunology, Faculty of Pharmacy, Port Said University, Port Said, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Surgical site infections (SSIs) are a significant cause of morbidity and mortality, often complicated by multidrug-resistant (MDR) pathogens and biofilm formation. This study evaluates the potential of a natural nanoemulsion containing chitosan, lavender, and curcumin, in combination with antimicrobial drugs, for treating SSIs. Methods: A comprehensive approach combining phenotypic and genotypic analyses, along with Results: The most common SSI pathogens identified were Conclusion: This study highlights chitosan nanoemulsion as an adjuvant therapy to combat antimicrobial resistance, enhance antibiotic efficacy, and improve SSI treatment outcomes. Further clinical studies are needed to optimize its use in patient care.

Indexed as

amikacinchitosan nanoemulsionhistopathologicalMDRSSIS

Identifiers

PMID40672366
PMCPMC12263955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.